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The dengue virus is the most common arbovirus in tropical and subtropical regions of 
the world. After analyzing the evolutionary history of the dengue virus, the health risks it 
presents, prevention methods, and the progress and setbacks that are currently being made in 
vaccine development, scientists understand the important role detection plays in combatting 
the virus. The research conducted in this thesis attempts to improve detection of the dengue 
virus using samples that were previously shown as negative by conventional RT-PCR but 
positive by ELISA. After designing new primers, conventional RT-PCR was able to detect 
22% of the dengue mutants. The results from qRT-PCR, ELISA, and conventional RT-PCR 
were compared with the clinical data to recognize any possible trends between viral 
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Overview.  According to the World Health Organization (WHO), the dengue virus 
poses a threat to over 2.5 billion people, about 40% of the world’s population. The Center for 
Disease Control and Prevention (CDC) estimates that every year the dengue virus affects 
over 100 million people, causing undifferentiated febrile illness, dengue fever, dengue 
hemorrhagic fever, and dengue shock syndrome. These conditions result in approximately 
500,000 hospitalizations and 24,000 deaths. Unfortunately, there is no vaccine to protect the 
human population from the virus, but researchers are working diligently at developing one in 
order to combat this threat to global humanity (Srikiatkachorn et al., 2010; Poersch et al., 
2005). 
The dengue virus is the most common arboviral infection of humans in tropical and 
subtropical regions of the world and is therefore considered the most important human 
pathogen of the arboviruses (Gibbons, 2010; Weaver and Vasilakis, 2009). The four 
serotypes of the virus are members of the genus Flavivirus and are spherical, lipid-enveloped 
particles approximately 50 nm and have a genome made up of a single positive-strand RNA 
(Guzmán and Kourí, 2004; Sadon et al., 2008). The virus is primarily transmitted by female 
Aedes aegypti but can also be transmitted by Aedes albopictus, both of which are very small 
mosquitoes that are known to occupy the tropical and subtropical regions of the world (Sadon 
et al., 2008).  
The dengue virus presents a troubling uniqueness in that there are four closely related 
serotypes known as DEN-1, DEN-2, DEN-3, and DEN-4. If infected by one serotype, the 




one of the other three serotypes more than 2-3 months after the primary infection, there is a 
higher risk of developing Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome 
(DSS) which are more severe than Dengue Fever (DF) (WHO, 2009). This is due to a 
phenomenon known as antibody-dependent enhancement (ADE) in which the antibodies 
produced during the primary infection actually aid in the entry of the second virus into the 
host cells resulting in a more severe form of the disease (Sadon et al., 2008). This 
phenomenon causes clinical complications as well as complications in vaccine development. 
As the virus continues to evolve and spread to various regions around the world, the 
methods utilized in research facilities must be efficient in the detection of dengue. This thesis 
presents previously conducted research to assess and improve the detection of the dengue 
virus circulating in Thailand using different laboratory tests. In addition to the main study, 
this thesis also highlights the importance of the study by connecting it to a variety of 
previously conducted studies and emphasizes its relevance to the common person.  
Epidemiology: History and Effects on Health in Thailand.  In order to understand 
the dengue virus, one must investigate its origin in human populations around the world and 
its dramatic impact on Thailand. In addition, the investigation must include when the virus 
first caused symptoms in humans and how the virus made its transition to the vulnerable 
human host. 
There is no agreement in the literature as to when the dengue virus first appeared 
because the symptoms experienced in humans are not distinctly diagnostic (Holmes and 
Twiddy, 2003). In a previous study, scientists noted that the earliest record of an infection 




A more recent article provides evidence that dengue infections date back even further to the 
3
rd
 century in China (Holmes and Twiddy, 2003; Weaver and Vasilakis, 2009). These records 
referred to the disease as “water poison” because it was associated with flying insects that 
surrounded water and caused fever, rash, arthralgia, myalgia, and sometimes hemorrhaging 
(Weaver and Vasilakis, 2009). In the late 18
th
 century, a disease resembling dengue caused 
intermittent epidemics in Asia and the Americas (Holmes and Twiddy, 2003). It is suspected 
that by the late 19
th
 and early 20
th
 centuries the dengue virus had made its way across most of 
the tropical and subtropical areas of the world that it currently affects today (Holmes and 
Twiddy, 2003). However, it was not until a little over 50 years later that the first well 
documented outbreak of DHF impacted Manila, Philippines. In 1958, an even larger outbreak 
struck Bangkok, Thailand, the country of focus for this study (Barbazan et al., 2002; Holmes 
and Twiddy, 2003).  
There are approximately 100 million cases of dengue infection occurring globally. 
The case fatality rate can be as high as 10-15% in certain countries (Gubler, 2002). Since the 
first DHF outbreak experienced by the city of Bangkok in 1958, Thailand has continually 
experienced an increase in the number of dengue infections. Children, especially under the 
age of 15, demonstrate the highest incidence of virus infection (Barbazan et al., 2002; 
Chareonsook et al., 1999; Wichmann et al., 2011).  According to an article published in the 
Bangkok Post on November 5, 2012, Dr. Suwitch Dhammapalo, director of Disease Control 
Office 12 in Songkhla, stated that since the beginning of 2012 the number of people that had 
confirmed infections with the dengue virus exceeded 55,000 with 52 fatalities as of October 
30, 2012 (Tropical Medical Bureau, 2012). It is very apparent from this data that the dengue 




Clinical Symptoms Manifestations. Since dengue infections are very common in 
Thailand and are quite complicated because of the similarities they share with other febrile 
diseases, Thai physicians and nurses are thoroughly trained to quickly diagnose and treat the 
signs and symptoms of a suspected dengue patient (Chareonsook et al., 1999; Wichmann et 
al., 2011). Infections caused by the dengue virus are so common that certain hospitals, such 
as the Queen Sirikit National Institute of Child Health, have their own dengue ward staffed 
by physicians that specialize in dengue treatment. This practice increases the efficiency of 
diagnosing and treating patients suffering from the disease. To diagnose and administer 
treatment for DF, DHF, and DSS, medical professionals must first recognize the particular 
symptoms and signs that the virus presents in its host.  
 Dengue infection may be asymptomatic, but most of the time it causes 
undifferentiated fevers, DF, DHF, and DSS. Most physicians base their diagnosis on the 
criteria provided by the WHO using clinical and hematological characteristics (Chareonsook 
et al., 1999; Sadon et al., 2008). According to the WHO criteria, dengue is suspected when 
the patient presents a high fever (usually 40°C or 104°F) and at least two of the following 
signs or symptoms: severe headache, pain behind eyes, muscle and joint pain, nausea, 
vomiting, swollen glands, or rash. These symptoms can exist anywhere between 2-7 days and 
usually occur a few days after a mosquito bite. 
DHF and DSS are usually more apparent, but can be difficult to assess, and will 
rapidly escalate and become dangerous. People experiencing these diseases are usually 
hospitalized and monitored closely.  In the cases of DHF, the patient first experiences 
symptoms similar to DF but within a few days the person’s temperature may drop slightly, 




symptoms continue to occur. These include enlarged liver, thrombocytopenia (platelet count 
of <100,000/mm
3
), rise in hematocrit >20%, bleeding gums, petechiae, increased rate of 
breathing, fatigue, and hypotension (Bakshi, 2007; Guzmán and Kourí, 2004; Sun et al., 
2011; WHO, 2013). At that point, complications arise in the patient and the risk of DSS and 
death is increases due to respiratory distress, plasma leakage, severe hemorrhaging, and 
circulatory failure (Bakshi, 2007; WHO, 2013). Patients usually recover as long as they 
receive sufficient intravenous fluid and electrolytes, but death can occur if this process is 
inadequate or delayed (Guzmán and Kourí, 2004). A major protocol when treating patients 
with suspected DF or DHF is to avoid aspirin and other nonsteroidal anti-inflammatory drugs 
(NSAIDs). These drugs if administered to a patient would only increase the severity of their 
symptoms as they can increase the risk of internal bleeding due to their ability to inhibit 
blood clotting. Acetaminophen is the preferred treatment for pain relief and fever reduction 
(Bakshi, 2007). 
Current Prevention for Dengue. There is currently no licensed vaccine accessible to 
the public for the dengue virus. Even if a licensed vaccine were released, no sufficient 
distribution method exists to vaccinate the 2.5 billion people at risk for the virus (Chao et al., 
2012). Surveillance and control systems must also be strengthened (Guzmán and Kourí, 
2003).  By understanding the modes of transmission and the behavior of the dengue virus 
vector, medical professionals can utilize resources to keep the rate of dengue virus infections 
from increasing. This will help contain the virus in areas where it is already endemic and 
prevent it from moving to regions of the world that have yet to experience its effects. 
Transmission can begin if a female mosquito ingests the blood of a person who 




infected with the virus itself. If this happens, the dengue virus incubates in the mosquito’s 
body for approximately 8-12 days and then can be transmitted to another human through a 
female mosquito bite. To make matters worse, the mosquito remains infective for the rest of 
its life and can pass the virus onto its offspring, making them capable of transmitting the 
virus to humans as well (Parker and Holman, 2012; WHO, 2009). 
Since mosquitoes, particularly A. aegypti, are the vectors for the dengue virus, 
prevention can be achieved (to some extent) by avoiding contact with mosquitoes in areas 
where the dengue virus is considered endemic. Precautions can include application of 
repellant containing DEET or Icaridin and wearing long sleeves and pants if planning to be 
outdoors for an extended period of time especially in the daylight hours, which is primarily 
when A. aegypti feeds (WHO, 2009). Mosquito netting around beds is highly encouraged to 
help prevent mosquitoes from biting individuals while asleep as well as installing screens on 
windows and doors to keep mosquitoes from entering buildings. Another important method 
of preventing the habitation of mosquitoes is to quickly rid property of any stagnant water 
that has collected after a rainstorm (Jansen and Beebe, 2010). Female mosquitoes lay their 
eggs on or around water surfaces near human habitation. Once the eggs develop into an 
embryo they can withstand dry conditions for up to a year and may develop into adults 
during the next rainy season (Jansen and Beebe, 2010). Lastly, it is important for people who 
are suspected of having DF or DHF to avoid mosquitoes more than the uninfected individual 
so that they don’t contribute to the mosquito-human-mosquito cycle. 
In addition to these methods of protection, organizational and governmental efforts to 
reduce the risk of mosquito proliferation in dengue endemic regions have been put in place in 




responsible for disposing of any waste containers that have the potential to accumulate water 
and clearing the drains so that they do not become places for larva to develop (WHO, 2009). 
As A. aegypti is an urban mosquito which can utilize buildings within the city as 
reproduction sites, many areas where dengue is endemic have adopted new regulations for 
the construction of buildings. In Singapore, for example, roof gutters are no longer permitted 
on buildings and those already in place must be removed or thoroughly maintained (WHO, 
2009). The WHO also recommends that larvicides and insecticides be sprayed around homes 
and other buildings two to three times a year during the morning or late afternoon. This 
method of control is fairly effective but can be toxic to humans; therefore, dengue 
management services must collaborate with epidemiological surveillance systems to ensure 
that pesticides are applied at the beginning of a dengue outbreak which typically happens 
during the rainy seasons, usually May-November, depending on the region.  
Reducing the spread of dengue by travelers is important in decreasing the global 
expansion of the virus and preventing outbreaks from occurring in other countries. For 
example, the deployment of troops during WWII correlated with the rapid globalization of 
dengue through the transportation of mosquitoes on ships, aircrafts, and automobiles 
(Wilder-Smith and Gubler, 2008). Today’s increased number of travelers from around the 
world has led to the introduction of mosquito abatement programs in international airports. 
These programs conduct routine sprayings of insecticides within the airport and passenger 
cabins of the aircrafts (Wilder-Smith and Gubler, 2008). Despite the installation of dengue 
prevention programs to help with the transmission and infection rate of the dengue virus, it is 
impossible to protect the world’s population from the virus. With this being the case, the race 




Evolution of the Virus. Historical records and research provide evidence that the 
dengue virus did not just suddenly emerge as the endemic and epidemic problems that 40% 
of humans face today. Scientists have observed the gradual development of dengue infections 
in humans by reconstructing a molecular time-scale demonstrating its evolution. By 
estimating the nucleotide substitution rates of 120 envelope genes, Holmes and Twiddy 
(2003) revealed that the dengue virus originated approximately 1,000 years ago as the “water 
poison” reported in Chinese medical encyclopedias. In the same study, they also discovered 
that cross-species transmission from monkeys to humans occurred within the last 125 to 320 
years (depending on the serotype). This led researchers to suggest that prior to the distinct 
divergence the virus showed only occasional outbreaks in human populations. It was 
suggested that the clear “break” into what is today the dengue virus’s major host was most 
likely caused by the rapid increase in human populations, urbanization and traveling. In 
addition, scientists have found a strong relationship between the period of World War II and 
the eruption of the dengue virus as a global health concern (Holmes and Twiddy, 2003; 
Wilder-Smith and Gubler, 2008).  
The site of the original cross-species transmission took place has been the subject of 
much controversy. Previous studies, established that A. aegypti have lived in urban areas, but 
researchers have discovered other mosquito species that have the ability to transmit the 
dengue virus to non-human primates. This mechanism is referred to as a sylvatic 
transmission cycle (Holmes and Twiddy, 2003; Wilder-Smith and Gubler, 2008). One area 
where these transmission cycles have been observed is Asia. In this case, the principal 
vectors were from the genus Ochlerotatus with its main hosts from the Presbytis and Macaca 




cycles was in West Africa where various Aedes species were able to transmit dengue to 
Erythrocebus patas monkeys (Holmes and Twiddy, 2003).  
From the discovery of these sylvatic transmission cycles, the possibility of cross-
species transmission began to emerge as an explanation which led to strain investigation in 
monkeys. These studies revealed that the DENV-2 and DENV-4 strains in Asian and West 
African monkeys are related to those of human strains, which may also be true of DENV-1 
(Holmes and Twiddy, 2003). In Malaysian monkeys, researchers have found antibodies for 
DENV-3 suggesting there is or once was a DENV-3 sylvatic transmission cycle as well 
(Holmes and Twiddy, 2003).  
Due to these observations a debate arose over Africa versus Asia as the origin of the 
dengue virus. Some scientists claim the virus emerged in Africa. This is based on the 
evidence that most other mosquito-borne flaviviruses circulate only in Africa and infect 
primates. Furthermore, A. aegypti is thought to have African origins (Holmes and Twiddy, 
2003; Wilder-Smith and Gubler, 2008). On the other hand, the fact that all four serotypes of 
the dengue virus appear in humans and primates in Asia strongly suggests that the cross-
species transmission of the four serotypes occurred independently of each other. (Holmes and 
Twiddy, 2003; Wilder-Smith and Gubler, 2008).  
Several recent findings suggest that the origin of certain dengue virus serotypes, 
especially specific genotypes, is somewhere in Southeast Asia. A study performed by 
Villabona-Arenas and Zanotto in 2011 concluded after studying 310 DENV-4 samples from 
37 countries between 1956 and 2008 that the most probable origin of DENV-4 was Malaysia 




occurrences of dengue in Malaysian monkeys. To further support Villabona-Arenas and 
Zanotto’s observations other studies have contributed molecular evidence that also suggests 
the origin of DENV-4 is Southeast Asia, most likely Thailand or Malaysia (Klungthong et 
al., 2004). When observing a different serotype, DENV-3, researchers found that the strain 
first appeared in 1890 with the major branching of genotypes occurring approximately 30 to 
40 years ago in Thailand, Indonesia, and Sri Lanka (Araújo et al., 2009).  
With respect to DENV-1, Patil et al. investigated different Indian genotype isolates 
sampled between 1962 and 2005. They discovered that these isolates were introduced into 
India through African and Singaporean roots and then exported to the Americas around the 
middle of the 20th century. Another noteworthy observation from their study was that the 
DENV-1 is approximately 123 years old (which is consistent with previous findings) and that 
the American-African genotype shared a common node with the Malaysian sylvatic genotype 
around that predicted time period. Lastly, a study conducted in 2004 by Foster et al. 
presented information that indicated that the 59 DENV-2 isolates collected between 1981 and 
2000 from ten of the Caribbean islands, two Central American countries, and six South 
American countries were of Southeast Asian origin. From these different phylogenic and 
evolutionary studies on all four serotypes of the dengue virus, scientists can confidently infer 
that the virus has some form of Asian origin. However, in order to actually pinpoint a 
particular region, further investigations into the geographical migration and the molecular 
time-scale of the dengue virus is needed. 
Immunological Response. The dengue virus displays antibody dependent 
enhancement, which presumably leads to DHF and DSS (Guzmán and Kourí, 2004; Kliks et 




disease spreading mechanism that causes individuals with a secondary infection to be more 
infectious, as compared to when they had a primary infection by a different strain (Billings et 
al., 2008). In most immunological processes, the human body produces antibodies in 
response to an infection in order to provide protection against a particular pathogen as well as 
similar pathogens (Adams and Boots, 2006). However, in some instances, such as the four 
strain dengue virus, ADE occurs and the antibodies developed in response to the first 
serotype infection form a complex with the second serotype. This actually facilitates the 
entry of the virus into more cells, thus increasing viral production (Adams and Boots, 2006; 
Billings et al., 2008). 
Recent research has revealed that cross-reactive non-neutralizing antibodies acquired 
after the primary infection have the potential to mediate an ADE of the second heterologous 
infection with the use of Fc receptors located on monocytes or macrophages (Guzmán and 
Kourí, 2004; Kliks et al., 1989; Schmidt, 2010; Sun et al., 2011). The three classes of FcγR 
serve as receptors on monocytes or macrophages for dengue virus entry in the forms of virus-
antibody immune complexes (Sun et al., 2011). Studies have shown that the highest binding 
affinity to these receptors corresponds with infection enhancement as well as suboptimal 
concentrations of the primary infection antibodies (Sun et al., 2011).  
From this discovery, researchers inferred that once the antibodies for the primary 
infection have dropped below a certain threshold, those antibodies fail to neutralize other 
serotypes of the dengue virus and instead help them enter the cells bearing the dengue 
receptors (Kliks et al., 1989; Schmidt, 2010; Sun et al., 2011). An additional correlation 
detected that IL-10, TNF-α, and IFN-α, cytokines produced by monocytes or macrophages, 




infections. By over secreting cytokines, there is a dangerous increase in the inflammatory 
response and cell permeability which is likely the cause of vesicular leakage and 
thrombocytopenia in DHF and DSS patients (Schmidt, 2010; Sun et al., 2011). 
Scientists have also discovered that CD4+ and CD+8 T cells play an important role in 
the ADE process (Guzmán and Kourí, 2004). When infected with a second serotype, memory 
T cells target the dengue virus-infected monocytes. The cells are lysed by cytokines. The 
release of enzymes and activators from within the cell causes plasma leakage and can 
potentially cause shock (Guzmán and Kourí, 2004). A research article published by Friberg 
et al. (2011) was the first to assess the cross-reactivity of the CD8+ repertoire produced after 
a primary infection in HLA-A* 1101+ individuals using in vitro binding with homologous 
and heterologous peptide variants found in the four DENV serotypes.  The reasoning behind 
demonstrating cross-reactivity using HLA-A* 1101+ individuals is that researchers have 
discovered that it is the common haplotype circulating within DENV endemic areas and has 
an association with the susceptibility of the dengue disease. This study demonstrated that 
sequential infections of DENV-1 and DENV-3 activate cross-reactive T cells that vigorously 
produce IFNγ. They also found that a secondary infection by DENV-2 caused poor T cell 
activity, but actually triggered an increase in TNFα production by monocytes that contribute 
to an increase in disease severity. Their results provided critical evidence that supports the 
previous epidemiological findings, which indicated that the order of the different DENV 
infections influences the effects of antibody dependent enhancement and the final clinical 
outcome a person experiences. 
From these studies, scientists have made strides into understanding this unique 




DHF and DSS. The collective findings of these and future studies can be utilized to develop 
vaccines, diagnose patients, and increase the effectiveness of treating persons infected with 
dengue. 
Vaccine Development. Dengue infections continue to increase in countries already 
affected by the virus, and now, as current epidemiological evidence shows, the virus is 
spreading to new areas such as the Middle East and the United States. Due to these findings, 
the development of an effective vaccine has become a main priority for many infectious 
disease researchers (Chao et al., 2012; Shepard et al., 2004). There is no doubt that even with 
diligent vector control, a vaccine is the only solution to decrease the number of infections 
that occur worldwide.  
ADE has turned the vaccination process for the dengue virus into quite the on-going 
challenge (Billings et al. 2008). Separate vaccinations in a series have been considered, but 
because of ADE, they pose a threat and are not believed to be the preventive method 
(Billings et al. 2008). Single serotype vaccines have been considered; however, if patients 
received a vaccine against a single serotype, they would only be protected against that 
particular serotype. Whitehead and colleagues constructed a DEN-4 vaccine candidate that 
produced 100% neutralizing antibody seroconversion in 24 adult volunteers (Billings et al. 
2008). This vaccine candidate could be applicable to an area of the world that only has that 
one serotype in existence, but regions of the world where dengue is a threat typically contain 
two or more serotypes. Thus, vaccination could actually do more harm than good, since an 
infection by a second serotype would be enhanced and cause increased health risks (Billings 




An optimal vaccine would need to protect against all strains of the disease 
simultaneously in order to prevent the increased transmission of the strains not covered 
(Billings et al. 2008). To further complicate development, such a vaccine could be 
particularly dangerous to individuals who already have antibodies for a particular serotype of 
dengue. Furthermore, previously infected persons and infants born to a dengue-immune 
mother are at risk (Billings et al. 2008; Kliks et al. 1989). Despite this, a tetravalent vaccine 
is seen as the most viable course of action (Bakshi, 2007; Thomas, 2011). A number of 
research facilities and companies are currently working on developing a tetravalent DENV 
vaccine and they are showing promising results.  
An article published by Watanaveeradej et al. tested the safety and immunogenicity 
of a tetravalent live-attenuated dengue vaccine in healthy infants who had not yet been 
infected with any of the four dengue serotypes (2011). A vaccine candidate was developed 
by the Walter Reed Army Institute of Research (WRAIR) and GlaxoSmithKline Biologicals 
(GSK) in hopes of protecting children and adults against all forms of the dengue virus.  The 
vaccine candidate was transported to Armed Forces Research Institute of Medical Sciences 
(AFRIMS) in Bangkok to be tested on Thai infants between 12 and 15 months of age. When 
preparing the vaccines, monovalent vaccines for each specific DENV serotype were 
developed and then blended together to make a tetravalent vaccine prior to injection. Each 
subject received two doses of the vaccine candidate in either full-dose or low-dose (1/10) 
forms spread over a six month period and had their neutralizing antibodies measured. The 
researchers also noted any reactions experienced by the recipients.  
The vaccine candidates showed promising results. Both the full-dose and low-dose 




pain at the injection site and fever for no longer than 3 days after the administration of each 
dose. This was similar to side effects shown with the control vaccine (Varicella and H. 
influenzae type B) recipients. None of the recipients experienced hemorrhaging or other 
serious adverse events from the administration of the DENV vaccines. The investigators 
determined that the low-dose vaccine was no clinically safer than the full-dose vaccine. With 
respect to immunogenicity, researchers were unable to detect any neutralizing antibodies in 
the control group but were able to detect them in the low-dose and full-dose recipients. The 
full-dose vaccine presented the best results with 85.7% of its recipients displaying trivalent or 
tetravalent neutralizing antibodies 30 days after the second dose. The low-dose vaccine 
presented lower immunogenicity and, therefore, would not be the best method of vaccination. 
Unfortunately, there was a significant decrease in neutralizing antibodies in the full-dose 
vaccine recipients a year after the second dose was administered especially with DENV-1 
and DENV-3. This suggests that something occurs within the first year of immunization and 
must be studied in order to produce an effective vaccine with long-term protection.  
This study presents great promise with respect to vaccine development for Thailand 
and the other countries currently at risk for dengue infections. Because the full-dose DENV 
vaccine was just as safe as the low-dose DENV but provoked a better immunological 
response particularly with DENV-2 and DENV-4, it can be concluded that a full-dose DENV 
vaccine is probably the best method of vaccination. They also determined that the age group 
used in this trial is an appropriate age to distribute a DENV vaccine. Nonetheless, this study 
introduces important questions that need to be answered to increase the immunogenicity of 




The vaccine candidate presented in the article above is one of the many vaccine 
candidates presently being tested in clinical trials (Chao et al., 2012). According to the WHO, 
the DENV vaccine candidate that has shown the most promising results, and is currently the 
farthest along in the clinical development process, is a live-attenuated tetravalent vaccine 
produced by Sanofi Pasteur. It is actually a chimeric yellow fever-dengue fever vaccine that 
is being evaluated in a phase IIb study which is taking place in the Ratchaburi Province, 
Thailand with 4,002 children between 4 and 11 years of age. In addition to this, a phase III 
study is underway in 31,000 children and adolescents in 10 countries in Asia and Latin 
America (WHO, 2012).  
Research indicates that a tetravalent vaccine is the best possible solution and will be 
the only means of decreasing dengue infection rates (Chao et al., 2012). Due to the 
complications discussed and presented by Chao et al., as well as various others, development 
of an effective vaccine to prevent the spreading of the dengue virus will be an on-going 
challenge. Until these challenges are overcome, there is currently no safe, licensed dengue 
vaccine available to the public and it is predicted that there will not be one for another 2 to 5 
years (Chao et al., 2012). 
 Research Project. After evaluating the impact of the dengue, it is easy to see that 
scientific progress needs to be made to further understand the virus. In order to do so, 
detection of all four serotypes is the essential first step. Due to the fact that the dengue virus 
is one of the biggest threats to humanity in the country of Thailand, AFRIMS in Bangkok has 
become an important research facility in the country and one of the leading global research 




as HIV, influenza, and Japanese encephalitis. AFRIMS was the site where the laboratory 
research portion of this thesis was conducted.  
Since 1994, AFRIMS has used a modified Lanciotti’s conventional reverse 
transcriptase polymerase chain reaction (RT-PCR) method to diagnose the dengue virus; 
however, the analysis of PCR results of 13,532 previously confirmed dengue cases by 
enzyme-linked immunosorbent assay (ELISA) tested over 11 years (2000-2010) showed 17-
42% negative conventional RT-PCR results (AFRIMS’s data). These results sparked a new 
research objective: to improve the detection and identification of the DENV in these dengue 
ELISA confirmed samples that were missed by conventional RT-PCR results. Because 
earlier studies analyzed only the positive RT-PCR samples, this increased the probability of 
missing possible dengue virus mutants. This study was one of the first to actually analyze 
previously negative RT-PCR samples to determine the efficiency of each method, and thus 
improve the system. 
Once the new research project was approved, laboratory personnel began making the 
effort to retrieve and analyze data to improve the previous method of detecting the dengue 
virus from specimens in the areas surrounding Bangkok. The prior methods included QRT-
PCR paired with either virus isolation in C6/36 cells with typing ELISA or mosquito 
inoculation followed by dengue ELISA. These two approaches were used to verify that the 
conventional RT-PCR cannot detect some DENV variances.  The positive samples by one of 
these two methods were examined for the conventional RT-PCR’s primer binding site 
regions on the DENV genome. New primers were designed based off the DENV mutants. 
Conventional RT-PCR tests were performed using these new primers to improve the 




MATERIALS AND METHODS 
Purpose. It was hypothesized that by discovering mutant strains of the dengue virus 
currently circulating in the Bangkok, Thailand region by assessing the negative conventional 
RT-PCR which tested positive with ELISA, new primers could be designed to improve the 
detection of arising mutant strains. By continuously improving methods of dengue virus 
detection, accurate research can be conducted which will provide advantageous information 
into the production of an effective vaccine and thus improve protection of mankind.  
Samples.  300 serum specimens, which previously tested positive for dengue primary 
and secondary infection using the AFRIMS Dengue IgM/IgG ELISA and negative by 
conventional RT-PCR, were randomly selected to be tested by in-house TaqMan
TM
 real time 
RT-PCR. Among these selected 300 samples, 35 were selected for virus isolation with 
ELISA typing. The samples with positive TaqMan
TM
 real-time RT-PCR and/or virus 
isolation with typing ELISA were then examined for the conventional RT-PCR’s primer 
binding site by sequencing. 
Viral RNA Extraction and Modified Lanciotti’s conventional RT-PCR. Viral 
RNA was extracted from serum specimens using QIAgen viral RNA extraction kits and 
following the manufacturer’s instructions. Modified Lanciotti’s conventional RT-PCR was 
performed in accordance with the method described in the Samples section above 
(Klungthong et al, 2007). 
Quantitative real time RT-PCR. The quantitative RT-PCR was performed by 
following AFRIMS’s standard operating procedure and provided for use in this study (Sadon 




 Virus isolation in C6/36 cells with typing ELISA. Virus isolation in C6/36 was 
performed with 35 samples in accordance with the previously described method (Klungthong 
et al, 2007). The positive isolates were then tested by typing ELISA. First, the microtiter 
wells were coated with goat anti-mouse IgG and left at 4°C for approximately 20 hours and 
then a specific monoclonal antibody was added to the wells. Following the addition of the 
first antibody which remained at room temperature for two hours, the test specimen was 
inserted into the well. After sitting at 4°C for approximately 20 hours, the wells were washed 
and the human anti-flavivirus IgG- HRP (second antibody) was added. Lastly, after sitting at 
37°C for one hour, the wells were washed a final time and the OPD substrate was added and 
the reaction was stopped. Positive results were then identified by the appearance of a yellow-
orange color inside the well. 
New primer design for conventional RT-PCR. All positive dengue isolates were 
subjected for sequencing of the primer binding sites on DENV genome to examine mutation. 
All obtained sequences were aligned with Lanciotti’s primers using Sequencher software.   
The new primers were designed to avoid the mismatch points between the primers and 
templates, then tested for efficiency on seven specimen that were known for containing 
dengue mutants.  
Conventional RT-PCR with new primers and gel electrophoresis. Due to the 
efficiency of the new primers, we decided to test them using conventional RT-PCR and gel 





Comparison of test results to clinical analysis. In order to determine if trends 
existed between the results from qRT-PCR, ELISA, and conventional RT-PCR with the new 
primers compared to the clinical analysis received from Queen Sirikit National Institute of 
Child Health and the hospital in Kamphaeng Phet, detection of the dengue virus positive 
results were compared with the disease severity (DF vs. DHF), type of infection (primary vs. 
secondary), temperature (≥ 38°C vs. < 38°C) and number of days with fever (0-4 vs. >4). In 
addition, this method of the research was used to address variation in the sensitivity between 





 Quantitative real time RT-PCR. Quantitative RT-PCR was performed on 300 
samples of dengue ELISA confirmed cases with negative conventional RT-PCR of which 
180 (60%) samples appeared positive for the dengue virus (Fig. 1). From those 180 samples 
that tested positive for the dengue virus, 129 (71.7%) were DEN-1, 39 (21.7%) were DEN-2, 
4 (2.2%) were DEN-3, and 8 (4.4%) were both DEN-1 and DEN-2.  
Virus isolation in C6/36 cells with typing ELISA. Virus isolation in C6/36 cells 
with typing ELISA performed with 35 samples selected from the 300 samples was able to 
identify 8 (22.86%) positive dengue isolates (Fig. 2). Of those 8 positive results, 4 (50%) 
were DEN-1, 3 (37.5%) were DEN-2, and 1 (12.5%) was DEN-3. 
 New primer design conventional RT-PCR (Fig.3). Sequences of the primer binding 
sites on the genome of all positive DENV isolates revealed two mismatches in the D1 primer 
(forward primer), nine mismatches in the D2 (universal reverse primer), five mismatches in 
the TS1 (DEN-1 specific reverse primer), two mismatches in TS2 (DEN-2 specific reverse 
primer), and two mismatches in TS3 (DEN-3 specific reverse primer). From these 
mismatches caused by the dengue virus mutants, new primers were designed with the hope of 
improving the detection of the dengue virus by conventional RT-PCR. These primers were 
then tested on the seven specimens known for containing the dengue mutants and displayed 
100% efficiency.  
 Conventional RT-PCR with new primers and gel electrophoresis. After running 















Figure 3. New primer sequences based off dengue mutants with mismatch sites shown in 
parentheses. For primers with mismatches shown, more than one primer was synthesized to 





11 (22%) were positive for the dengue virus (Table 1). Of those 11 positive samples, six 
(54.5%) were DEN-1, four (36.4%) were DEN-2, and one (9.1%) was DEN-3. When 
comparing the results of these positive samples with their qRT-PCR results, ten conventional 
RT-PCR samples matched their qRT-PCR serotype and one sample was positive for DEN-1 
by conventional RT-PCR but negative by qRT-PCR.  
Comparison of test results to clinical analysis (Table 2). For persons classified as 
having DF, 65.9% of positive samples were detected by qRT-PCR, 27.8% of the positive 
samples were detected by ELISA, and 20.8% of the positive samples were detected by 
conventional RT-PCR. For those having DHF, 39.3% of positive samples were detected by 
qRT-PCR, 20% of the positive samples were detected by ELISA, and 22.4% of positive 
samples were detected by conventional RT-PCR.  
 For persons classified as having a primary infection, 76.3% of positive samples were 
detected by qRT-PCR, 50% of positive samples were detected by ELISA, and 42.9% of 
positive samples were detected by conventional RT-PCR. For those having a secondary 
infection, 55.7% of positive samples were detected by qRT-PCR, 19.4% of positive samples 
were detected by ELISA, and 14.3% of positive samples were detected by conventional RT-
PCR.  
 For persons classified as having a fever of 38°C or higher, 61.7% of positive samples 
were detected by qRT-PCR, 38.5% of positive samples were detected by ELISA, and 33.3% 
of positive samples were detected by conventional RT-PCR. For those having a fever less 









Analysis qRT-PCR Virus Isolation Conventional-PCR (New Primer)
DF 65.79 27.78 20.83
   DHF 39.34 20 22.37
Primary 76.27 50 42.86
    Secondary 55.65 19.35 14.29
Fever Day 0-4 63.3 15.63 30
Fever Day >4 57.4 100 16.67
Temp. >=38°C 61.73 38.46 33.33
    Temp. <38°C 60.1 15 18.42
Serotype DEN-1,2,3 DEN-1,2,3 DEN-1,2,3




were detected by ELISA, and 18.4% of positive samples were detected by conventional RT-
PCR.  
Lastly, for patients classified as having a fever for up to 4 days, 63.3% of positive 
samples were detected by qRT-PCR, ELISA detected 15.6% of the positive samples, and 
30% of positive samples were detected by conventional RT-PCR. For those patients 
classified as having a fever for more than four days, 57.4% of positive samples were detected 
by qRT-PCR, ELISA detected 100% of the positive samples, and 16.7% of positive samples 
were detected by conventional RT-PCR. It must also be noted that only DENV-1, 2, and 3 





Analysis of Study. Once the results were compared and analyzed it was apparent that 
each method can detect the dengue virus differently depending on the patient’s clinical 
analysis. When analyzing the results for disease severity, qRT-PCR (65.8%) and ELISA 
(27.78%) detected the dengue virus better in samples from DF patients than DHF patients. 
Conventional RT-PCR detected the dengue virus fairly equally in samples from DHF patients 
and DF patients. These results suggest that when testing patient serum in those suspected of 
DF, qRT-PCR and ELISA are more reliable. On the other hand, when testing patient serum 
in those suspected of DHF, conventional RT-PCR or qRT-PCR should be used. 
When analyzing the results for infection type, all three of the methods detected the 
dengue virus in samples from patients with a primary infection better than in samples from 
patients with a secondary infection suggesting that all these tests are better at detecting the 
dengue virus in a primary infection. It is important to note that qRT-PCR showed a higher 
percentage (76.3% for primary and 55.7% for secondary) of detection for both types of 
infection overall. Because of this finding, it is suggested that qRT-PCR be used to test serum 
samples in both primary and secondary infections rather than ELISA and conventional RT-
PCR. 
When analyzing the results for degree of temperature, ELISA (38.5%) and 
conventional RT-PCR (33.3%) detected the dengue virus in samples from patients with a 
fever of 38°C or higher better than in samples from patients with a fever less than 38°C, 




was able to detect the virus with the highest percentage (~61.0%) at both temperature ranges, 
it is suggested that qRT-PCR be used with regards to these conditions. 
Lastly, when analyzing the results based on number of days with fever, qRT-PCR 
(63.3%) and conventional RT-PCR (30.0%) detected the dengue virus in samples from 
patients who had a fever up to 4 days better than in samples from patients who had a fever 
greater than 4 days. ELISA (100%), however, was able to detect the dengue virus better in 
samples from patients who had a fever for more than four days than in samples from patients 
who had a fever for 0-4 days. From these results, qRT-PCR and conventional RT-PCR 
should be used to detect the virus in sera from patients with a fever for up to 4 days while 
ELISA should be used for those with fevers greater than 4 days.  
It can be concluded from the results that qRT-PCR typically was the best of the three 
tests when detecting the dengue virus. These findings are consistent with those in a previous 
study where researchers assessed the effectiveness of dengue virus detection when using 
qRT-PCR and conventional RT-PCR (Sadon et al., 2008). These researchers found that both 
qRT-PCR and conventional RT-PCR provide similar sensitivity but one can provide more 
reliable results depending upon the serotype. QRT-PCR was found to be more sensitive for 
DENV-1 and DENV-3 while conventional RT-PCR was found to be more sensitive for 
DENV-4 (Sadon et al., 2008). ELISA was suggested to be less efficient and accurate due to 
cross-reactivity among flaviviruses and the fact that it requires more time (Sadon et al., 
2008). This information should be received with caution, however, because according to 
other findings conducted across various fields of microbiology, qRT-PCR can be less 
sensitive than conventional RT-PCR and can also lose sensitivity if performed too fast 




as compared to the clinical analyses, each method is important in the detection and therefore 
to the research being conducted on the dengue virus. Our study was one of the first to 
actually analyze previously negative RT-PCR samples to determine the efficiency of each 
method. In contrast, earlier studies analyzed only the positive RT-PCR samples, likely 
increasing the potential of missing possible dengue virus mutants.  
Caution must be taken when collecting specimens because the dengue virus is easily 
altered by heat and must be delivered to the laboratory fairly quickly in order to isolate the 
virus, or it must be stored for a short period of time at 4°C (Guzmán and Kourí, 2004).   In 
this research, the RNA samples were stored for four months at -70°C as recommended but 
after reviewing the results, it is suggested that fresh RNA samples be utilized for the future. 
Though proper storage methods can increase the life of RNA samples, there is a possible risk 
of RNAse contamination and RNA degradation due to alkaline hydrolysis by the additional 
2’ hydroxyl group present in RNA (IDT, 2013). Such fresh samples should be used in 
conjunction with updated PCR primers and compared to the clinical analysis acquired so that 
AFRIMS can continue to improve the detection and diagnosis of the dengue virus in the 
circulating area of Bangkok, Thailand. In the future, the sample sizes used in assessing 
conventional RT-PCR and ELISA should be increased in order to decrease the chances of 
sampling error. 
For additional improvement, researchers will implement external quality assurance 
(EQA) which assesses the efficiency and accuracy of dengue molecular diagnosis methods 
applied by expert laboratories (Domingo et al., 2010). Finally, this research study provided 
the laboratory personnel at AFRIMS with a further understanding of how the dengue virus is 




the widely used method of confirming the diagnosis of dengue in a patient through methods 
such as those in this study, the findings from this research are important for future diagnosis 
and possible vaccination production (Guzmán and Kourí, 2004; Nisalak et al., 2003; Jarman 
et al., 2011). 
Conclusion. Ever since the first major outbreak of DHF in Bangkok in 1958, the dengue 
virus has been the research focus for Thailand as well as much of the world.  It continues 
today to be one of the top infectious diseases posing a global threat. Preventive measures 
have been enforced to keep the virus from spreading but the only way to defeat the virus and 
bring infection rates to a lower level is through vaccine development and distribution. There 
are currently several tetravalent vaccine candidates advancing to clinical trials; however, 
their development must conquer the many challenges the dengue virus presents, which will 
involve a few more years of observation and research. In order to obtain such a scientific 
feat, research conducted on a molecular scale is essential and must be performed with the 
upmost efficiency. The research presented in this thesis provides information for the 
improvement of detecting and diagnosing the dengue virus so that scientists can track it and 
better understand how it is evolving. Furthermore, this research indirectly affects the 
advances made in vaccine development which in turn helps in the fight against the dengue 
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